SI0917466T1 - Oral contraceptive - Google Patents

Oral contraceptive

Info

Publication number
SI0917466T1
SI0917466T1 SI9730679T SI9730679T SI0917466T1 SI 0917466 T1 SI0917466 T1 SI 0917466T1 SI 9730679 T SI9730679 T SI 9730679T SI 9730679 T SI9730679 T SI 9730679T SI 0917466 T1 SI0917466 T1 SI 0917466T1
Authority
SI
Slovenia
Prior art keywords
combination
daily dosage
phase
administered
days
Prior art date
Application number
SI9730679T
Other languages
Slovenian (sl)
Inventor
Michael Jay Gast
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24757747&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI0917466(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth filed Critical Wyeth
Publication of SI0917466T1 publication Critical patent/SI0917466T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

This invention provides a method of contraception which comprises administering to a female of child bearing age for 23-25 consecutive days, a first phase combination of a progestin at a daily dosage of 40-500 mu g trimegestone, 250 mu g - 4mg dienogest, or 250 mu g - 4mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 mu g ethinyl estradiol for 3-8 days beginning on day 1 of the menstrual cycle, wherein the same dosage of the progestin and estrogen combination is administered in each of the 3-8 days, a second phase combination of a progestin at a daily dosage of 40-500 mu g trimegestone, 250 mu g - 4 mg dienogest, or 250 mu g - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 mu g ethinyl estradiol, for 4-15 days, beginning on the day immediately following the last day of administration of the first phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days, and a third phase combination of a progestin at a daily dosage of 40-500 mu g trimegestone, 250 mu g - 4 mg dienogest, or 250 mu g - 4 mg drospirenone, and an estrogen at a daily dosage equivalent in estrogenic activity to 10-20 mu g ethinyl estradiol, for 4-15 days beginning on the day immediately following the last day of administration of the second phase combination, wherein the same dosage of the progestin and estrogen combination is administered in each of the 4-15 days provided that the daily dosage of the combination administered in the first phase is not the same as the daily dosage of the combination administered in the second phase and that the daily dosage of the combination administered in the second phase is not the same as the daily dosage of the combination administered in the third phase.
SI9730679T 1996-07-26 1997-07-23 Oral contraceptive SI0917466T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68678696A 1996-07-26 1996-07-26
EP97935047A EP0917466B1 (en) 1996-07-26 1997-07-23 Oral contraceptive
PCT/US1997/012786 WO1998004268A1 (en) 1996-07-26 1997-07-23 Oral contraceptive

Publications (1)

Publication Number Publication Date
SI0917466T1 true SI0917466T1 (en) 2005-02-28

Family

ID=24757747

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9730679T SI0917466T1 (en) 1996-07-26 1997-07-23 Oral contraceptive

Country Status (17)

Country Link
EP (1) EP0917466B1 (en)
JP (1) JP2000515888A (en)
KR (1) KR100501021B1 (en)
CN (1) CN1119999C (en)
AT (1) ATE278406T1 (en)
AU (1) AU713016B2 (en)
BR (1) BR9710565A (en)
CA (1) CA2261687A1 (en)
DE (1) DE69731092T2 (en)
DK (1) DK0917466T3 (en)
ES (1) ES2229378T3 (en)
HU (1) HUP9904345A3 (en)
IL (1) IL127923A (en)
NZ (1) NZ333862A (en)
PT (1) PT917466E (en)
SI (1) SI0917466T1 (en)
WO (1) WO1998004268A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344462C2 (en) 1993-12-22 1996-02-01 Schering Ag Composition for contraception
FR2754179B1 (en) 1996-10-08 1998-12-24 Theramex NOVEL HORMONONAL COMPOSITION AND ITS USE
EP2044941A1 (en) * 1999-08-31 2009-04-08 Bayer Schering Pharma AG Multiple-phase formulation of drospirenone and estradiol as a contraceptive
FR2801218B1 (en) * 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc PHARMACEUTICAL COMPOSITIONS COMPRISING TRIMEGESTONE, THEIR PREPARATION METHODS AND THE PRIMARY PACKAGING CONTAINING THEM
US7297688B2 (en) * 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
WO2005092441A2 (en) * 2004-03-19 2005-10-06 Warner Chilcott Company, Inc. Extended cycle multiphasic oral contraceptive method
DE102004019743B4 (en) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Multiphase preparation for contraception based on natural estrogen
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US7704984B2 (en) * 2005-04-22 2010-04-27 Warner Chilcott Company, Llc Extended estrogen dosing contraceptive regimen
DE102005034498A1 (en) * 2005-07-20 2007-01-25 Grünenthal GmbH Oral contraception with Trimegeston
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
MX2008011074A (en) * 2006-03-02 2008-09-10 Warner Chilcott Co Inc Extended cycle multiphasic oral contraceptive method.
EP1930010A1 (en) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2365103C3 (en) * 1973-12-21 1980-08-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Use of hormones for contraception
US4628051A (en) * 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
DK174071B1 (en) * 1987-09-24 2002-05-21 Jencap Res Ltd Contraceptive preparation in the form of a package comprising unit doses
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
IE62665B1 (en) * 1990-12-17 1995-02-22 Akzo Nv Contraceptive regimen
DE4313926A1 (en) * 1993-04-28 1994-11-03 Jenapharm Gmbh Multiphase pharmaceutical product for hormonal contraception
NL9301562A (en) * 1993-09-09 1995-04-03 Saturnus Ag Substitution therapy preparation.
DE4344462C2 (en) * 1993-12-22 1996-02-01 Schering Ag Composition for contraception
DE4411585A1 (en) * 1994-03-30 1995-10-05 Schering Ag Combined pharmaceutical preparation for hormonal contraception
DE4429374C1 (en) * 1994-08-12 1996-02-01 Jenapharm Gmbh Pharmaceutical preparations for contraception / hormone substitution with biogenic estrogen component

Also Published As

Publication number Publication date
IL127923A0 (en) 1999-11-30
EP0917466A1 (en) 1999-05-26
HUP9904345A2 (en) 2000-06-28
KR20000029537A (en) 2000-05-25
AU3807697A (en) 1998-02-20
CN1119999C (en) 2003-09-03
DE69731092T2 (en) 2005-02-10
NZ333862A (en) 2000-08-25
CA2261687A1 (en) 1998-02-05
EP0917466B1 (en) 2004-10-06
JP2000515888A (en) 2000-11-28
CN1230888A (en) 1999-10-06
HUP9904345A3 (en) 2000-11-28
ES2229378T3 (en) 2005-04-16
ATE278406T1 (en) 2004-10-15
WO1998004268A1 (en) 1998-02-05
KR100501021B1 (en) 2005-07-18
IL127923A (en) 2004-07-25
DE69731092D1 (en) 2004-11-11
BR9710565A (en) 1999-08-17
AU713016B2 (en) 1999-11-18
PT917466E (en) 2004-12-31
DK0917466T3 (en) 2004-12-20

Similar Documents

Publication Publication Date Title
DE69729956D1 (en) ORAL, ONE-STEP CONCEPT PREVENTION METHOD AND COMBINATION PRODUCT CONTAINING THE STAGE AND ESTROGEN
US5418228A (en) Contraceptive regimen
CY1105276T1 (en) TRIPHASIC ORAL CONTRACEPTIVE
AU7537987A (en) Combination dosage form for pre-menopausal women
WO1998004246A3 (en) Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen
IL127923A0 (en) Oral contraceptive
AU4043597A (en) Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen